(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 January 2013 (10.01.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/006837 A1

(51) **International Patent Classification**:
*A61K 9/107* (2006.01) *A61K 47/24* (2006.01)
*A61K 39/00* (2006.01) *A61K 47/06* (2006.01)

(21) **International Application Number**:
PCT/US2012/045845

(22) **International Filing Date**:
6 July 2012 (06.07.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

| | | |
|---|---|---|
| 61/505,109 | 6 July 2011 (06.07.2011) | US |
| 61/545,936 | 11 October 2011 (11.10.2011) | US |
| 61/585,641 | 11 January 2012 (11.01.2012) | US |

(71) **Applicant** *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **BRITO, Luis** [US/US]; Novartis Vaccines and Diagnostics, Inc, IP Services M/S X-100B, 4560 Horton Street, Emeryville, CA 94608-2916 (US). **CHAN, Michelle** [US/US]; Novartis Vaccines and Diagnostics, Inc, IP Services M/S X-100B, 4560 Horton Street, Emeryville, CA 94608-2916 (US). **GEALL, Andrew** [GB/US]; Novartis Vaccines and Diagnostics, Inc, IP Services M/S X-100B, 4560 Horton Street, Emeryville, CA 94608-2916 (US). **O'HAGAN, Derek** [GB/US]; Novartis Vaccines and Diagnostics, Inc, IP Services M/S X-100B, 4560 Horton Street, Emeryville, CA 94608-2916 (US). **SINGH, Manmohan** [US/US]; Novartis Vaccines and Diagnostics, Inc, IP Services M/S X-100B, 4560 Horton Street, Emeryville, CA 94608-2916 (US).

(74) **Agents**: **LEE, Helen** et al.; Novartis Vaccines and Diagnostics, Inc, IP Services M/S X-100B, P.O. Box 8097, Emeryville, CA 94662-8097 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published**:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2013/006837 A1

(54) **Title**: CATIONIC OIL-IN-WATER EMULSIONS

(57) **Abstract**: This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oihlipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid- based vaccines.